Ovarian Cysts and Tumors for NEET PG 2026: Diagnosis, Staging, Treatment

Master ovarian cysts and tumors for NEET PG 2026 — functional cysts, benign and malignant tumors, RMI, IOTA, FIGO 2014 staging, BRCA, chemotherapy, MCQ traps.

Management — observe; haemodynamically stable rupture managed conservatively; emergency surgery if haemoperitoneum.

Theca lutein cysts

Pathology — bilateral, multilocular, large cysts caused by markedly elevated beta-HCG.

Associations — complete hydatidiform mole, choriocarcinoma, multiple gestation, ovarian hyperstimulation syndrome.

Management — resolve spontaneously after the underlying HCG-producing process is treated.

Benign tumors

Serous cystadenoma

Pathology — unilocular, thin-walled cyst lined by ciliated tubal-type epithelium; clear serous fluid. Bilateral in 15 to 25 percent.

Demographics — peak age 30 to 50 years.

Treatment — cystectomy in young women, oophorectomy in older or post-menopausal.

Mucinous cystadenoma

Pathology — multilocular, large (often above 15 cm — "ovarian giant"), lined by intestinal or endocervical-type mucin-producing epithelium. Rarely bilateral (5 percent).

Complication — rupture causing pseudomyxoma peritonei (mucinous ascites — often actually appendiceal in origin).

Mature cystic teratoma (dermoid)

Pathology — germ cell tumour containing tissues from all three germ layers (ectoderm dominant — hair, sebaceous material, teeth). The classic "Rokitansky protuberance" on USG.

Demographics — commonest ovarian tumour in young women (10 to 30 years).

Imaging — heterogeneous mass with hyperechoic foci (fat, calcification), shadowing tip-of-iceberg sign.

Complications — torsion (10 to 15 percent), rupture, chemical peritonitis, malignant transformation (1 percent — usually squamous cell carcinoma in postmenopausal women), infection.

Treatment — laparoscopic cystectomy preserving ovary in young women.

Brenner tumour

Pathology — rare; epithelial tumour with transitional-cell (urothelial-like) nests in fibrous stroma. Usually small, solid, unilateral, benign.

Borderline tumors (tumors of low malignant potential)

Pathology — epithelial proliferation and atypia without stromal invasion. Serous and mucinous subtypes.

Behaviour — indolent; 90 percent five-year survival even at advanced stage.

Treatment — surgical staging plus oophorectomy. Conservative fertility-sparing surgery (unilateral salpingo-oophorectomy) in young women with stage I. No adjuvant chemotherapy.

Malignant tumors

Epithelial ovarian carcinoma (90 percent of malignancies)

Subtypes

• High-grade serous carcinoma (HGSC) — most common (70 percent); BRCA1/2 mutations in 15 to 20 percent; p53 mutations universal. Fallopian-tube origin (STIC lesions) increasingly accepted.
• Low-grade serous carcinoma — KRAS/BRAF mutations; relatively chemoresistant; better prognosis.
• Mucinous carcinoma — must exclude GI primary; KRAS mutations.
• Endometrioid carcinoma — associated with endometriosis and Lynch syndrome.
• Clear cell carcinoma — endometriosis-associated; chemoresistant; higher thromboembolism risk.

Risk factors — increasing age, nulliparity, early menarche, late menopause, BRCA1/2 mutation, Lynch syndrome, hormone replacement therapy, endometriosis (clear cell, endometrioid).

Protective — multiparity, breastfeeding, oral contraceptive pill (50 percent reduction after 5 years), tubal ligation, salpingectomy.

Presentation — vague abdominal bloating, early satiety, urinary urgency, pelvic pain. The "ovarian cancer symptom index" includes any of these symptoms more than 12 days per month with onset within the past year — should trigger pelvic USG and CA-125.

Germ cell tumors (5 percent)

Affect young women (under 30 years).

• Dysgerminoma — commonest malignant germ cell; female counterpart of seminoma; bilateral in 10 percent; LDH elevated; very radiosensitive and chemosensitive.
• Endodermal sinus (yolk sac) tumour — Schiller-Duval bodies on histology; AFP elevated; rapidly growing in adolescents.
• Embryonal carcinoma — both AFP and beta-HCG elevated.
• Choriocarcinoma — beta-HCG very high; haemorrhagic, lung metastases.
• Immature teratoma — graded by neuroepithelial content; the only teratoma that is malignant; can secrete AFP.

Treatment — BEP chemotherapy (bleomycin, etoposide, cisplatin); fertility-sparing surgery often feasible.

Sex cord stromal tumors (5 percent)

• Granulosa cell tumour — Call-Exner bodies on histology; inhibin and estradiol secretion (precocious puberty in juvenile type, postmenopausal bleeding and endometrial hyperplasia or carcinoma in adult type — always sample endometrium).
• Theca cell tumour (thecoma) — estrogen-secreting, benign; postmenopausal bleeding.
• Fibroma — benign; Meigs syndrome (ascites, right pleural effusion); resolves with resection.
• Sertoli-Leydig cell tumour — androgen-secreting (virilisation); Reinke crystals.

Metastatic tumors

• Krukenberg tumour — bilateral solid ovarian metastases from a GI primary (most often gastric signet-ring carcinoma); poor prognosis.

Risk stratification

Tumour markers

Risk of Malignancy Index (RMI)

RMI = Menopausal status × Ultrasound score × CA-125 (IU/mL)

Ultrasound features: multilocular cyst, solid areas, bilateral, ascites, metastases.

RMI above 200 — refer to gynaecological oncology centre (78 percent sensitivity, 87 percent specificity).

IOTA Simple Rules

International Ovarian Tumor Analysis group offers 5 benign (B) and 5 malignant (M) ultrasound features. If only M features are present, classify as malignant; if only B features, benign; mixed or none, indeterminate (consider MRI or refer).

Surgical staging — FIGO 2014

Staging is surgical — exploratory laparotomy with washings, omentectomy, peritoneal biopsies, pelvic and para-aortic lymphadenectomy, total abdominal hysterectomy with bilateral salpingo-oophorectomy.

Treatment

Early-stage (I, IIA)

• Surgery — TAH plus BSO plus comprehensive staging.
• Adjuvant chemotherapy — carboplatin plus paclitaxel for 3 to 6 cycles (stage IC and above; high-grade lesions).
• Fertility-sparing — unilateral salpingo-oophorectomy with comprehensive staging in stage IA grade 1 to 2 disease in young women.

Advanced-stage (III, IV)

• Primary cytoreductive (debulking) surgery — aim for residual disease less than 1 cm (R1) or ideally no visible residual disease (R0).
• Adjuvant chemotherapy — carboplatin plus paclitaxel × 6 cycles.
• Bevacizumab — added in stage III-IV per GOG-218 / ICON7.
• PARP inhibitor maintenance — olaparib (BRCA mutated), niraparib (all-comers), rucaparib. SOLO1, PRIMA, ATHENA-MONO trials.
• Neoadjuvant chemotherapy plus interval debulking — option when primary R0 unlikely (EORTC 55971, CHORUS).
• HIPEC — hyperthermic intraperitoneal chemotherapy after interval debulking, per OVHIPEC trial (modest benefit).

Germ cell tumours

• Surgery — unilateral salpingo-oophorectomy plus staging.
• Chemotherapy — BEP × 3 to 4 cycles; cure rates above 90 percent.

Sex cord stromal

• Surgery — staging plus removal; consider sampling endometrium for granulosa cell.
• Adjuvant — selected high-risk; BEP for advanced.

BRCA testing and risk-reducing surgery

All high-grade epithelial ovarian, fallopian tube, and primary peritoneal carcinoma patients should be offered germline BRCA1/2 testing regardless of family history (NCCN 2025, ICMR 2024).

• BRCA1 — 40 to 60 percent lifetime ovarian cancer risk; offer risk-reducing bilateral salpingo-oophorectomy (RR-BSO) at age 35 to 40 after completion of childbearing.
• BRCA2 — 15 to 25 percent lifetime risk; RR-BSO at age 40 to 45.
• Lynch syndrome — 5 to 12 percent ovarian cancer risk; RR-BSO plus hysterectomy at age 40.

Salpingectomy at time of hysterectomy or sterilisation is now offered prophylactically given fallopian-tube origin of HGSC.

NEET PG MCQ traps

1. Most common ovarian tumour overall — mature cystic teratoma (in young) or serous cystadenoma (in adults).
2. Most common malignant ovarian tumour — serous cystadenocarcinoma.
3. Most common germ cell malignancy — dysgerminoma.
4. Schiller-Duval bodies — yolk sac tumour, AFP elevated.
5. Call-Exner bodies — granulosa cell tumour, inhibin elevated.
6. Reinke crystals — Sertoli-Leydig tumour, virilisation.
7. Krukenberg tumour — bilateral, signet-ring cells, GI primary (gastric).
8. Meigs syndrome — fibroma plus ascites plus right pleural effusion; resolves with surgery.
9. Theca lutein cysts — bilateral, with molar pregnancy or OHSS.
10. Mucinous tumours — must rule out appendiceal/GI primary; pseudomyxoma peritonei is usually appendiceal.
11. Granulosa cell tumour — postmenopausal bleeding; sample the endometrium for hyperplasia/carcinoma.
12. OCP protection — at least 5 years of use halves ovarian cancer risk; strongest in BRCA carriers (controversial breast risk).

Recent updates and Indian context

• SOLO1 (2018) — olaparib maintenance after first-line platinum-based chemotherapy in BRCA-mutated advanced ovarian cancer reduced progression by 70 percent.
• PRIMA (2019) — niraparib maintenance benefits all-comers, with greatest effect in HRD-positive tumours.
• NCCN 2025 — BRCA testing for all high-grade epithelial ovarian cancers; HRD testing to guide PARP-inhibitor selection.
• Indian late presentation — Tata Memorial Hospital data show 75 percent of Indian ovarian cancer patients present at stage III-IV due to absence of population-based screening; CA-125 plus TVS screening has not improved mortality (UKCTOCS) and is not recommended for general population.
• PMJAY coverage — covers debulking surgery and platinum-based chemotherapy; PARP inhibitors are expensive (Lynparza about 4 lakhs/month) but Indian generic olaparib (Cipla, Natco) reduced cost by 60 percent in 2024.
• NEET PG / NEXT alignment — high-yield topics are RMI calculation, FIGO 2014 staging, BRCA-related risk reduction, tumour markers, and Krukenberg / Meigs eponyms.

Frequently asked questions

What is the most common ovarian malignancy?

Epithelial ovarian carcinoma accounts for 90 percent of ovarian malignancies. Serous carcinoma is the commonest subtype (70 percent of epithelial), followed by mucinous, endometrioid, clear cell, and Brenner tumours. High-grade serous carcinoma carries BRCA1/2 mutations in 15 to 20 percent of cases. Median age at diagnosis is 63 years globally; presentations in India tend to be 8 to 10 years younger.

What is the Risk of Malignancy Index (RMI)?

RMI is calculated as menopausal status (1 if pre-menopausal, 3 if post-menopausal) multiplied by ultrasound score (1 if 0 to 1 features, 3 if 2 or more features — multilocular, solid areas, bilateral, ascites, metastases) multiplied by serum CA-125 in IU/mL. An RMI above 200 suggests malignancy with 78 percent sensitivity and 87 percent specificity. Such patients require referral to a gynaecological oncology centre.

What is Meigs syndrome?

Meigs syndrome is the triad of a benign ovarian fibroma (sex cord stromal tumour), ascites, and right-sided pleural effusion that resolves completely after tumour resection. Pseudo-Meigs syndrome describes the same triad with other benign or malignant pelvic tumours including mucinous cystadenoma, Brenner tumour, and metastatic ovarian carcinoma — important to distinguish.

When should BRCA testing be offered?

BRCA1/2 germline testing is recommended for all women with high-grade epithelial ovarian, fallopian tube, or primary peritoneal carcinoma regardless of family history (per NCCN 2025 and ICMR 2024). Carriers face 40 to 60 percent lifetime ovarian cancer risk (BRCA1) and 15 to 25 percent (BRCA2). Risk-reducing bilateral salpingo-oophorectomy at age 35 to 40 (BRCA1) or 40 to 45 (BRCA2) after childbearing is recommended.

What is the standard chemotherapy for ovarian cancer?

Carboplatin plus paclitaxel every 3 weeks for 6 cycles is the global standard for adjuvant treatment of epithelial ovarian cancer (stage IC and above) after debulking surgery. PARP inhibitors (olaparib, niraparib) are added as maintenance therapy in BRCA-mutated or homologous recombination deficient tumours. Bevacizumab is added to carboplatin-paclitaxel in advanced stages. Germ cell tumours use BEP (bleomycin, etoposide, cisplatin).

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: May 2026